Charles River Labs (CRL) Stock Forecast & Price Target

Compare

566 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRL Analyst Ratings

Moderate Buy

5 Buy

8 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Charles

River Labs

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$164.45

▼(-1.82% Downside)

Based on 13 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $164.45 with a high forecast of $182.00 and a low forecast of $140.00. The average price target represents a -1.82% change from the last price of $167.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"115":"$115","147":"$147","179":"$179","211":"$211","243":"$243"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$182.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":164.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$164.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[115,147,179,211,243],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.4,156.52307692307693,158.64615384615385,160.76923076923077,162.8923076923077,165.01538461538462,167.13846153846154,169.26153846153846,171.3846153846154,173.5076923076923,175.63076923076923,177.75384615384615,179.87692307692308,{"y":182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.4,155.17307692307693,155.94615384615386,156.71923076923076,157.4923076923077,158.26538461538462,159.03846153846155,159.81153846153845,160.58461538461538,161.3576923076923,162.13076923076923,162.90384615384613,163.67692307692306,{"y":164.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.4,153.2923076923077,152.1846153846154,151.0769230769231,149.96923076923076,148.86153846153846,147.75384615384615,146.64615384615385,145.53846153846155,144.43076923076924,143.3230769230769,142.2153846153846,141.1076923076923,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":203.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.08,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.96,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.31,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":145.99,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":116.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$182.00

Average Price Target$164.45

Lowest Price Target$140.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$162

Hold

-3.28%

Downside

Reiterated

08/07/25

Charles River Labs' overall stock score is primarily influenced by strong operational cash flows and strategic corporate changes. However, recent declines in revenue and profitability, coupled with a negative P/E ratio, present significant challenges. The technical indicators suggest potential bearish momentum, though the stock is nearing oversold conditions. The mixed sentiment from the earnings call and strategic board changes provide a cautiously optimistic outlook.

Michael RyskinBank of America Securities

Bank of America Securities

$155→$170

Hold

1.50%

Upside

Reiterated

07/18/25

Charles River Labs (CRL) Receives a Hold from Bank of America Securities

Unknown AnalystCFRA

Not Ranked

CFRA

$165

Hold

-1.49%

Downside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Charles RhyeeTD Cowen

TD Cowen

$105→$179

Buy

6.87%

Upside

Reiterated

07/11/25

Patrick B DonnellyCiti

Citi

―

Buy

―

Upgraded

07/09/25

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Charles River Labs (NYSE: CRL)

Luke SergottBarclays

Barclays

$155

Hold

-7.46%

Downside

Reiterated

06/25/25

Charles River Labs (CRL) Gets a Hold from Barclays

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$170

Buy

1.50%

Upside

Reiterated

06/04/25

Evercore ISI Reaffirms Their Buy Rating on Charles River Labs (CRL)

Max SmockWilliam Blair

William Blair

―

Hold

―

Reiterated

06/03/25

William Blair Remains a Hold on Charles River Labs (CRL)

Jamie ClarkRedburn Atlantic

Redburn Atlantic

$188→$182

Buy

8.66%

Upside

Upgraded

05/23/25

Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic

Tejas SavantMorgan Stanley

Morgan Stanley

$184→$168

Hold

0.30%

Upside

Reiterated

05/09/25

Mixed Signals and Uncertainty: Hold Rating on Charles River Labs Amid Strong DSA Performance and RMS Challenges

Dan LeonardUBS

UBS

$185→$150

Hold

-10.44%

Downside

Reiterated

05/08/25

Charles River Labs (CRL) PT Lowered to $150 at UBSUBS analyst Dan Leonard lowered the price target on Charles River Labs (NYSE: CRL) to $150.00 (from $185.00) while maintaining a Neutral rating.

Eric ColdwellRobert W. Baird

Robert W. Baird

$118→$140

Hold

-16.41%

Downside

Reiterated

05/08/25

Charles River price target raised to $140 from $118 at BairdCharles River price target raised to $140 from $118 at Baird

Casey WoodringJ.P. Morgan

J.P. Morgan

$165→$145

Hold

-13.43%

Downside

Reiterated

05/07/25

Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (NASDAQ: EYPT), Charles River Labs (NYSE: CRL) and Innoviva (NASDAQ: INVA)

Justin BowersDeutsche Bank

Deutsche Bank

$140→$180

Buy

7.47%

Upside

Reiterated

05/07/25

Charles River Labs (CRL) PT Raised to $180 at Deutsche BankDeutsche Bank analyst Justin Bowers raised the price target on Charles River Labs (NYSE: CRL) to $180.00 (from $140.00) while maintaining a Buy rating.

David WindleyJefferies

Jefferies

$169→$100

Hold

-40.29%

Downside

Reiterated

04/21/25

Charles River Labs (CRL) PT Lowered to $100 at JefferiesJefferies analyst David Windley lowered the price target on Charles River Labs (NYSE: CRL) to $100.00 (from $169.00) while maintaining a Hold rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$162

Hold

-3.28%

Downside

Reiterated

08/07/25

Michael RyskinBank of America Securities

Bank of America Securities

$155→$170

Hold

1.50%

Upside

Reiterated

07/18/25

Charles River Labs (CRL) Receives a Hold from Bank of America Securities

Unknown AnalystCFRA

Not Ranked

CFRA

$165

Hold

-1.49%

Downside

Downgraded

07/14/25

CFRA downgrades Charles River Labs (CRL) to a Hold

Charles RhyeeTD Cowen

TD Cowen

$105→$179

Buy

6.87%

Upside

Reiterated

07/11/25

Patrick B DonnellyCiti

Citi

―

Buy

―

Upgraded

07/09/25

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Charles River Labs (NYSE: CRL)

Luke SergottBarclays

Barclays

$155

Hold

-7.46%

Downside

Reiterated

06/25/25

Charles River Labs (CRL) Gets a Hold from Barclays

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$170

Buy

1.50%

Upside

Reiterated

06/04/25

Evercore ISI Reaffirms Their Buy Rating on Charles River Labs (CRL)

Max SmockWilliam Blair

William Blair

―

Hold

―

Reiterated

06/03/25

William Blair Remains a Hold on Charles River Labs (CRL)

Jamie ClarkRedburn Atlantic

Redburn Atlantic

$188→$182

Buy

8.66%

Upside

Upgraded

05/23/25

Charles River upgraded to Buy from Neutral at Redburn AtlanticCharles River upgraded to Buy from Neutral at Redburn Atlantic

Tejas SavantMorgan Stanley

Morgan Stanley

$184→$168

Hold

0.30%

Upside

Reiterated

05/09/25

Mixed Signals and Uncertainty: Hold Rating on Charles River Labs Amid Strong DSA Performance and RMS Challenges

Dan LeonardUBS

UBS

$185→$150

Hold

-10.44%

Downside

Reiterated

05/08/25

Charles River Labs (CRL) PT Lowered to $150 at UBSUBS analyst Dan Leonard lowered the price target on Charles River Labs (NYSE: CRL) to $150.00 (from $185.00) while maintaining a Neutral rating.

Eric ColdwellRobert W. Baird

Robert W. Baird

$118→$140

Hold

-16.41%

Downside

Reiterated

05/08/25

Charles River price target raised to $140 from $118 at BairdCharles River price target raised to $140 from $118 at Baird

Casey WoodringJ.P. Morgan

J.P. Morgan

$165→$145

Hold

-13.43%

Downside

Reiterated

05/07/25

Analysts Conflicted on These Healthcare Names: EyePoint Pharmaceuticals (NASDAQ: EYPT), Charles River Labs (NYSE: CRL) and Innoviva (NASDAQ: INVA)

Justin BowersDeutsche Bank

Deutsche Bank

$140→$180

Buy

7.47%

Upside

Reiterated

05/07/25

David WindleyJefferies

Jefferies

$169→$100

Hold

-40.29%

Downside

Reiterated

04/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

1 Month

xxx

Success Rate

6/10 ratings generated profit

Average Return

+2.10%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.10% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+6.72%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +6.72% per trade.

1 Year

Patrick B DonnellyCiti

Success Rate

9/12 ratings generated profit

Average Return

+16.93%

upgraded a buy rating last month

Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +16.93% per trade.

2 Years

xxx

Success Rate

9/12 ratings generated profit

Average Return

+15.75%

upgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +15.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRL has received 13 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the past 3 months is 164.45.

Each month's total comprises the sum of three months' worth of ratings.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $2.35 with a range of $2.30 to $2.45. The previous quarter’s EPS was $3.12. CRL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year CRL has Preformed in-line its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $975.42M with a range of $944.90M to $1.01B. The previous quarter’s sales results were $1.03B. CRL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year CRL has Preformed in-line its overall industry.

CRL Stock Forecast FAQ

What is CRL’s average 12-month price target, according to analysts?

Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 164.45.

What is CRL’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CRL, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRL a Buy, Sell or Hold?

Charles River Laboratories Intl has a consensus rating of Moderate Buy which is based on 5 buy ratings, 8 hold ratings and 0 sell ratings.

What is Charles River Laboratories Intl’s price target?

The average price target for Charles River Laboratories Intl is 164.45. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $182.00 ,the lowest forecast is $140.00. The average price target represents -1.82% Decrease from the current price of $167.49.

What do analysts say about Charles River Laboratories Intl?

Charles River Laboratories Intl’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of CRL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Charles River Labs (CRL) Stock Forecast & Price Target

CRL Analyst Ratings

CRL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Charles River Labs

CRL Analyst Recommendation Trends

CRL Financial Forecast

CRL Earnings Forecast

CRL Sales Forecast

CRL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts